Tweet
Multiple Sclerosis and Related Disorders
Available online 18 March 2021
Depression in multiple sclerosis: Is one approach for its management enough?
DanielleJones1RobertMotl1Brian M.Sandroff2
https://doi.org/10.1016/j.msard.2021.102904
Highlights
•Depression is highly prevalent and poorly-managed in persons with multiple sclerosis (MS).
•There is limited evidence for the efficacy of pharmacological treatments for depression in MS.
•There is weak evidence for the use behavioral treatments for depression in MS.
•Currently, there is no gold-standard, single treatment for depression in MS.
•Combinatory treatments may be efficacious for treating MDD and managing its consequences in MS.
Abstract
Background
Major depression disorder (MDD) and severe depression symptoms are highly prevalent in multiple sclerosis (MS). Depression can worsen symptoms of MS and is associated with significantly reduced quality of life and increased risk of suicide. Currently, there is no gold-standard, single treatment available for depression in MS. Pharmacotherapy, cognitive behavior therapy (CBT), and exercise training individually are moderately, yet incompletely, efficacious for managing depression in the general population and MS.
Purpose
This review provides an overview of evidence from meta-analyses and systematic reviews for current treatments of depression in persons with MS. This review further develops the rationale for using a combinatory treatment approach in persons with MS.
Methods
We performed a narrative review of meta-analyses and systematic reviews regarding the current state of evidence for the three most common treatments of depression in persons with MS (i.e., antidepressant medication, cognitive-behavior therapy, and exercise training). We provide a concise assessment of the overall effect of these treatments on depression in the general population and then persons with MS. We further note short-comings of research on these treatment for depression.
Conclusion
There is no single, gold-standard treatment for depression in MS, and we proposed that combinatory treatments should be considered for the management of depression in MS. However, there is a paucity of evidence for the use of combinatory therapy on depression and its outcomes in persons with MS, and this supports direct examination of the feasibility and efficacy of such combinatory approaches for MDD in MS.
Available online 18 March 2021
Depression in multiple sclerosis: Is one approach for its management enough?
DanielleJones1RobertMotl1Brian M.Sandroff2
https://doi.org/10.1016/j.msard.2021.102904
Highlights
•Depression is highly prevalent and poorly-managed in persons with multiple sclerosis (MS).
•There is limited evidence for the efficacy of pharmacological treatments for depression in MS.
•There is weak evidence for the use behavioral treatments for depression in MS.
•Currently, there is no gold-standard, single treatment for depression in MS.
•Combinatory treatments may be efficacious for treating MDD and managing its consequences in MS.
Abstract
Background
Major depression disorder (MDD) and severe depression symptoms are highly prevalent in multiple sclerosis (MS). Depression can worsen symptoms of MS and is associated with significantly reduced quality of life and increased risk of suicide. Currently, there is no gold-standard, single treatment available for depression in MS. Pharmacotherapy, cognitive behavior therapy (CBT), and exercise training individually are moderately, yet incompletely, efficacious for managing depression in the general population and MS.
Purpose
This review provides an overview of evidence from meta-analyses and systematic reviews for current treatments of depression in persons with MS. This review further develops the rationale for using a combinatory treatment approach in persons with MS.
Methods
We performed a narrative review of meta-analyses and systematic reviews regarding the current state of evidence for the three most common treatments of depression in persons with MS (i.e., antidepressant medication, cognitive-behavior therapy, and exercise training). We provide a concise assessment of the overall effect of these treatments on depression in the general population and then persons with MS. We further note short-comings of research on these treatment for depression.
Conclusion
There is no single, gold-standard treatment for depression in MS, and we proposed that combinatory treatments should be considered for the management of depression in MS. However, there is a paucity of evidence for the use of combinatory therapy on depression and its outcomes in persons with MS, and this supports direct examination of the feasibility and efficacy of such combinatory approaches for MDD in MS.